$SURF News
Last published 3y ago
- 3y agoCHRSSURFSurface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote "FOR" the Proposed Merger with Coherus BioSciencesGlobeNewswireCAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF) ("Surface"), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor
- 3y agoAMEDDBTXRETASURFMoore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoSURFSurface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023GlobeNewswireCAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today
- 3y agoCFMSNEWRPACWSURFMoore Kuehn Encourages PACW, NEWR, CFMS, and SURF Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoDICENETINEXSURFMoore Kuehn Encourages SURF, NEX, NETI, and DICE Investors to Contact Law FirmPR NewswireNEW YORK, June 20, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoKDNYNETINEXSURFMoore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law FirmGlobeNewswireNEW YORK, June 16, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoCHRSSURFCoherus to Acquire Surface OncologyGlobeNewswire– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition
- 3y agoSURFSurface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023GlobeNewswireUpdated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding into the third
- 3y agoSURFSurface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023GlobeNewswireCAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today
- 3y agoSURFSurface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023GlobeNewswireCAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today
- 3y agoSURFSurface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022GlobeNewswireSRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with
- 3y agoSURFSurface Oncology to Participate in the Cowen 43rd Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today
- 3y agoSURFSurface Oncology to Participate in the 2023 Guggenheim Oncology Days ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today
- 3y agoSURFVCNXVaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface OncologyGlobeNewswireROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the
- 3y agoSURFSurface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid TumorsGlobeNewswireSRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial
- 3y agoSURFStudy of SRF114 in Patients With Advanced Solid Tumors - NCT05635643ClinicalTrials.gov[Part A] Rate of Dose Limiting Toxicity (DLT), [Part B] Confirmed objective response rate (ORR), [Part A, Part B] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs), (and 6 more...)
- 4y agoSURFSurface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual MeetingGlobeNewswireCAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today
- 4y agoSURFSurface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination CohortGlobeNewswire– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year – – Company focusing resources on advancement
- 4y agoSURFVIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388GlobeNewswire– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine –– Study elucidates how SRF388 binds to IL-27 to prevent interaction with the IL-27 receptor, inhibiting the cytokine's
- 4y agoSURFSurface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society MeetingGlobeNewswire- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition - - Findings support the ongoing clinical investigation of SRF388 in multiple
- 4y agoSURFSurface Oncology to Participate in the Baird 2022 Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief
- 4y agoSURFSurface Oncology to Participate in the Gilmartin Group Emerging Growth Company ShowcaseGlobeNewswireCAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief e
- 4y agoSURFSurface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022GlobeNewswire– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization – – Interim SRF617 clinical data anticipated in the fourth q
- 4y agoSURFSurface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief e
- 4y agoSELBSURFSurface Oncology Appoints Carsten Brunn to Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D.,
- 4y agoSURFSurface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular CarcinomaGlobeNewswire- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer - CAMBRIDGE, Mass., June 20, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developin
- 4y agoSURFSurface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company grant
- 4y agoSURFSurface Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief e
- 4y agoSURFSurface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire– SRF388 demonstrated clinical activity in multiple solid tumor types withthree confirmed partial responses across NSCLC, RCC and HCC – – Data support continued evaluation of SRF388 in NSCLC, RCC, and first line HCC – – Surface plans to i
- 4y agoSURFSurface Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief ex
- 4y agoATERBTTXCOOKRDBX+1Thinking about buying stock in Better Therapeutics, Surface Oncology, Redbox Entertainment, Aterian, or Traeger?PR NewswireNEW YORK, May 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BTTX, SURF, RDBX, ATER, and COOK. To
- 4y agoSURFSurface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022GlobeNewswire– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $21 million raised in the quarter through ATM facility – – Expanding open label
- 4y agoSURFSurface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company grante
- 4y agoSURFSurface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual MeetingGlobeNewswireCAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will share a clini
- 4y agoSURFSurface Oncology Named one of the 2022 Best Places to Work by Boston Business JournalGlobeNewswireCAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognize
- 4y agoSURFSurface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung CancerGlobeNewswireRandomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients with previously-treated non-small-cell l
- 4y agoSURFSurface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewswireCAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new pre
- 4y agoSURFSurface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Surface's board
- 4y agoSURFSurface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 StudyGlobeNewswireCAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the first patient has been
- 4y agoSURFSurface Oncology Appoints Theresa Boni as General CounselGlobeNewswireCAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Theresa
- 4y agoSURFSurface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021GlobeNewswireContinued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types Company continues to guide to cash runway through 2023 CAMBRID
- 4y agoSURFSurface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen's 42nd Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief e
- 4y agoSURFSurface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology SummitGlobeNewswireCAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that company management will
- 4y agoSURFSurface Oncology Appoints Denice Torres as Chair of the Board of DirectorsGlobeNewswireBiopharma veteran Ben Hickey appointed to Board of Directors Lisa McGrath promoted to chief people officer; Shannon Devens promoted to senior vice president, development operations CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Surface Oncol
- 4y agoSURFSurface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021GlobeNewswireCAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that new data from the ongoi
- 4y agoSURFSurface Oncology Named a 2021 Top Place to Work by the Boston GlobeGlobeNewswireCAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company was named one of the Top
- 4y agoSURFSurface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021GlobeNewswireCAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation s
- 4y agoSURFSurface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIGGlobeNewswireCAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug
- 5y agoSURFPreclinical Data Supporting Therapeutic Potential of Surface Oncology's Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual MeetingGlobeNewswireCAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that two scientific posters
- 5y agoSURFSurface Oncology to Participate in the 2021 Annual Cowen IO Next SummitGlobeNewswireCAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief e